Investment Thesis
Aclarion is a pre-revenue medical laboratory services company with severe operational losses and minimal commercialization progress. Despite holding substantial cash reserves relative to its small asset base, the company is burning capital rapidly with -$7.2M operating cash flow on just $75.7K in revenue, indicating the business model has not achieved product-market fit. The near-total absence of profitability metrics and inability to generate positive cash flow make this a highly speculative venture-stage company unsuitable for fundamental investors.
Strengths
- Strong cash position ($12.0M) provides 15+ months of runway at current burn rate
- Minimal leverage (0.00x debt-to-equity) eliminates solvency risk in near term
- Exceptional liquidity ratios (14.81x current ratio) allow operational flexibility
Risks
- Catastrophic operating losses (-$7.1M) on minimal revenue ($75.7K) indicates failed commercialization
- Negative free cash flow of -$7.2M unsustainable without additional capital raises or revenue acceleration
- Medical laboratory sector requires significant regulatory approval and customer validation that company has not demonstrated
- Cash burn trajectory suggests funding runway exhaustion without material revenue growth
- No insider purchases in 90 days suggests lack of confidence from company leadership
Key Metrics to Watch
- Revenue growth rate and path to positive unit economics
- Monthly cash burn rate and projected runway duration
- Operating cash flow inflection toward breakeven
- Customer acquisition metrics and contract pipeline
- Regulatory approvals or clinical validation milestones
Financial Metrics
Revenue
75.7K
Net Income
-7.2M
EPS (Diluted)
$-13.61
Free Cash Flow
-7.2M
Total Assets
13.7M
Cash
12.0M
Profitability Ratios
Gross Margin
9.0%
Operating Margin
-9,312.5%
Net Margin
-9,551.9%
ROE
-56.4%
ROA
-52.9%
FCF Margin
-9,488.6%
Balance Sheet & Liquidity
Current Ratio
14.81x
Quick Ratio
14.81x
Debt/Equity
0.00x
Debt/Assets
6.1%
Interest Coverage
-110.05x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-19T10:50:11.661081 |
Data as of: 2025-12-31 |
Powered by Claude AI